Efter 2. dosis udviklede 95- 99% af spædbørnene > 0, 15 µg/ ml anti- PRP.
Post-dose 2, 95% to 99% of infants developed > 0.15 µg/ ml of anti-PRP, a level associated with short-term protection against invasive Hib disease, and the GMTs ranged from 2.5 µg/ ml to 4.3 µg/ ml.